Business Description
UroGen Pharma Ltd
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
UR8.Germany0XOD.UKURGN.USA Description
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.3 | |||||
| Equity-to-Asset | -0.49 | |||||
| Debt-to-Equity | -1.17 | |||||
| Debt-to-EBITDA | -0.89 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -6.47 | |||||
| Beneish M-Score | -3.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 210.2 | |||||
| 3-Year EBITDA Growth Rate | 6 | |||||
| 3-Year EPS without NRI Growth Rate | -1.1 | |||||
| 3-Year FCF Growth Rate | -16.8 | |||||
| 3-Year Book Growth Rate | -59.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.59 | |||||
| 9-Day RSI | 49.97 | |||||
| 14-Day RSI | 52.34 | |||||
| 6-1 Month Momentum % | 13.68 | |||||
| 12-1 Month Momentum % | 21.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.4 | |||||
| Quick Ratio | 6.14 | |||||
| Cash Ratio | 5.05 | |||||
| Days Inventory | 243.73 | |||||
| Days Sales Outstanding | 58.49 | |||||
| Days Payable | 199.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.82 | |||||
| Operating Margin % | -126 | |||||
| Net Margin % | -175.16 | |||||
| ROA % | -78.72 | |||||
| ROIC % | -547.07 | |||||
| ROC (Joel Greenblatt) % | -1021.02 | |||||
| ROCE % | -71.16 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.36 | |||||
| EV-to-EBIT | -2.26 | |||||
| EV-to-EBITDA | -2.31 | |||||
| EV-to-Revenue | 3.07 | |||||
| EV-to-Forward-Revenue | 1.91 | |||||
| EV-to-FCF | -2.22 | |||||
| Earnings Yield (Greenblatt) % | -44.25 |
